Literature DB >> 32067866

Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.

Jeremy D Osko1, David W Christianson2.   

Abstract

Histone deacetylase 6 (HDAC6) is associated with multiple neurological disorders as well as aggressive cancers, making its selective inhibition highly desirable for therapeutic purposes. The basic molecular design of an effective HDAC6 inhibitor consists of a zinc-binding group, a linker, and a capping group capable of making interactions at the mouth of the active site. To date, more than 50 high-resolution X-ray crystal structures of HDAC6-inhibitor complexes have been reported, many of which reveal intermolecular interactions that contribute to isozyme affinity and selectivity. Here, we review the key features of HDAC6 inhibitor design illuminated by these structural studies.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Enzyme; Inhibitor; X-ray crystallography

Mesh:

Substances:

Year:  2020        PMID: 32067866      PMCID: PMC7067655          DOI: 10.1016/j.bmcl.2020.127023

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  61 in total

1.  Three proteins define a class of human histone deacetylases related to yeast Hda1p.

Authors:  C M Grozinger; C A Hassig; S L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 2.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

3.  Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp.

Authors:  Kanchan Taori; Valerie J Paul; Hendrik Luesch
Journal:  J Am Chem Soc       Date:  2008-01-19       Impact factor: 15.419

Review 4.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

5.  Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected].

Authors:  Ju-Hee Lee; Yuanshan Yao; Adaickapillai Mahendran; Lang Ngo; Gisela Venta-Perez; Megan L Choy; Ronald Breslow; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-14       Impact factor: 11.205

Review 6.  HDACs and HDAC Inhibitors in Cancer Development and Therapy.

Authors:  Yixuan Li; Edward Seto
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

7.  Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases.

Authors:  Kathryn E Cole; Daniel P Dowling; Matthew A Boone; Andrew J Phillips; David W Christianson
Journal:  J Am Chem Soc       Date:  2011-07-26       Impact factor: 15.419

8.  Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.

Authors:  Janet S Kerr; Sheila Galloway; Armando Lagrutta; Michael Armstrong; Thomas Miller; Victoria M Richon; Paul A Andrews
Journal:  Int J Toxicol       Date:  2009-11-10       Impact factor: 2.032

Review 9.  The growing landscape of lysine acetylation links metabolism and cell signalling.

Authors:  Chunaram Choudhary; Brian T Weinert; Yuya Nishida; Eric Verdin; Matthias Mann
Journal:  Nat Rev Mol Cell Biol       Date:  2014-08       Impact factor: 94.444

10.  Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors.

Authors:  Geneviève P Delcuve; Dilshad H Khan; James R Davie
Journal:  Clin Epigenetics       Date:  2012-03-12       Impact factor: 6.551

View more
  7 in total

1.  Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.

Authors:  Jeremy D Osko; David W Christianson
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2020-08-19       Impact factor: 1.056

2.  Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.

Authors:  Priya Poonia; Monika Sharma; Prakash Jha; Madhu Chopra
Journal:  Mol Divers       Date:  2022-10-10       Impact factor: 3.364

3.  Dihydropyrazole-Carbohydrazide Derivatives with Dual Activity as Antioxidant and Anti-Proliferative Drugs on Breast Cancer Targeting the HDAC6.

Authors:  Irving Balbuena-Rebolledo; Astrid M Rivera-Antonio; Yudibeth Sixto-López; José Correa-Basurto; Martha C Rosales-Hernández; Jessica Elena Mendieta-Wejebe; Francisco J Martínez-Martínez; Ivonne María Olivares-Corichi; José Rubén García-Sánchez; Juan Alberto Guevara-Salazar; Martiniano Bello; Itzia I Padilla-Martínez
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-31

4.  Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.

Authors:  Olasunkanmi O Olaoye; Paris R Watson; Nabanita Nawar; Mulu Geletu; Abootaleb Sedighi; Shazreh Bukhari; Yasir S Raouf; Pimyupa Manaswiyoungkul; Fettah Erdogan; Ayah Abdeldayem; Aaron D Cabral; Muhammad Murtaza Hassan; Krimo Toutah; Andrew E Shouksmith; Justyna M Gawel; Johan Israelian; Tudor B Radu; Niyati Kachhiyapatel; Elvin D de Araujo; David W Christianson; Patrick T Gunning
Journal:  J Med Chem       Date:  2021-02-12       Impact factor: 7.446

Review 5.  Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.

Authors:  Alexandria M Chan; Steven Fletcher
Journal:  RSC Med Chem       Date:  2020-12-11

6.  Histone Deacetylase 6 Knockout Mice Exhibit Higher Susceptibility to Influenza A Virus Infection.

Authors:  Mark Zanin; Jennifer DeBeauchamp; Gowthami Vangala; Richard J Webby; Matloob Husain
Journal:  Viruses       Date:  2020-07-06       Impact factor: 5.048

7.  First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement.

Authors:  Daniel Herp; Johannes Ridinger; Dina Robaa; Stephen A Shinsky; Karin Schmidtkunz; Talha Z Yesiloglu; Theresa Bayer; Raphael R Steimbach; Corey J Herbst-Gervasoni; Annika Merz; Christophe Romier; Peter Sehr; Nikolas Gunkel; Aubry K Miller; David W Christianson; Ina Oehme; Wolfgang Sippl; Manfred Jung
Journal:  Chembiochem       Date:  2022-06-10       Impact factor: 3.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.